Login
Companies $AVBP
$11.56 +$0.00 (0.0%) After hours
ArriVent BioPharma, Inc. logo

ArriVent BioPharma, Inc.

arrivent.com

What Do They Do?

Develops cancer medicines, including firmonertinib for patients with uncommon lung-cancer mutations and antibody-drug conjugates for people with solid tumors.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
Net income
▼ −15% (Loss)
vs −$35M in Q3 FY2025
  • Nov 6, 2026 Firmonertinib missed its Phase 3 trial's primary endpoint The trial did not meet its primary progression-free-survival endpoint; the company is reviewing the full dataset to inform potential next steps.
  • Aug 11, 2026 Licensed ARR-002 rights in Greater China to Allist Allist is responsible for development and commercialization in the territory; ArriVent retains rights outside it.

Who Do They Compete With?

Competes with AstraZeneca, Johnson & Johnson, Blossom Hill Therapeutics, Dizal Pharmaceutical, Oric Pharmaceuticals, Black Diamond Therapeutics, Cullinan Therapeutics, Taiho Pharmaceutical, Boehringer Ingelheim, and Bayer

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support